A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
a study on Prostate Cancer
Neuroendocrine Prostate Cancer De novo or treatment emergent neuroendocrine prostate cancer Delta-like protein 3 (DLL3) Non-canonical Notch ligand Prostatic Neoplasms Tarlatamab
Lead Scientist at UCSF
- Rahul Aggarwal
I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.